Physician profile
Ryan Dunn
NPI 1114258167
$30,096.78
in general payments reported to CMS, 2019-2025
8 companies · $543 in 2025
The $543 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,244 · 2020: $7,098 · 2021: $5,353 · 2022: $1,925 · 2023: $20.08 · 2024: $5,915 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,017 · Travel and Lodging: $1,897 · Food and Beverage: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,017.38 |
| Travel and Lodging | $1,896.64 |
| Food and Beverage | $563.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23,319.38 | 2019-2025 | Jascayd |
| Intuitive Surgical, INC. | $5,896.64 | 2024 | |
| Glaxosmithkline, LLC. | $334.15 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $324.42 | 2025 | Tezspire, Airsupra, Breztri |
| Genentech USA, INC. | $100.52 | 2019-2020 | |
| United Therapeutics Corporation | $50.80 | 2021-2025 | Tyvaso, Steen Solution |
| Insmed, INC. | $50.54 | 2025 | Brinsupri, Arikayce |
| Inogen, INC. | $20.33 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.